17 results
P
patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA)
I/C
coeliac disease (CD), biopsy-confirmed CD in RA and JIA patients
O
pooled prevalence estimates of biopsy-confirmed CD and positive CD serology
P
cancer patients
I/C
immune checkpoint inhibitors (ICIs), higher PIV
O
shorter overall survival (OS) and progression-free survival (PFS)
P
Yu X, Xu R, Zhang Z, Yang Y, Deng F
I/C
extra-short implants (≤ 6 mm), longer implants (≥ 8 mm)
O
bone augmentation
P
Fenland Study, FinnGen Study, PLCO Atlas Project, Pan-UK Biobank
I/C
lactase-phlorizin hydrolase (LPH), colorectal cancer (CRC)
O
direct causal relationship
P
pediatric, adult
I/C
smokeless tobacco (SLT), oral potentially malignant disorders (OPMDs), head and neck cancer (HNC)
O
prevalence of use, association
P
5293
I/C
total glucosides of paeony, placebo, standard treatment
O
disease activity score (ASDAS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tumor necrosis factor (TNF)-α, interleukin (IL)-6, 28 joints disease activity (DAS28), psoriasis area and severity index (PASI), visual analogue scale (VAS), nitric oxide (NO)
P
people being investigated for tuberculosis
I/C
Xpert MTB/RIF, smear microscopy
O
mortality, proportion of participants starting tuberculosis treatment who had a successful treatment outcome, proportion of participants who were treated for tuberculosis, proportion of participants with bacteriological confirmation who were lost to follow-up pre-treatment, proportion of treated participants who had bacteriological confirmation
P
patients with oncologic and nononcologic indications
I/C
FAP-specific PET imaging and radionuclide therapy, detection rates of FAPI avidity
O
high radiolabeled FAPI avidity as early as 10 minutes after administration in primary sites of various malignant tumors
P
patients with autoimmune disease and associated inflammatory ocular diseases
I/C
Janus kinase (JAK) inhibitors, . None of these 11 patients responded adequately to conventional treatments, including biological agents; these were all refractory cases and switched to JAK inhibitor therapy.
O
all 11 patients showed an improvement to JAK inhibitors without significant side effects
P
patients with chronic myeloid leukemia (CML)
I/C
ponatinib, a third-generation TKI, current first-line TKIs
O
effectiveness, feasibility, and safety of ponatinib in real-life clinical management of CML